Kinetic Effect of Novel Osmium(VIII) for the Oxidation of Pyrazinamide by a Copper(III) Complex and Their Mechanistic Aspects

被引：2

作者：

Bagwan U.F.R. ^{[1
]}

Teradale A.B. ^{[2
]}

Shaikh I.N. ^{[1
]}

Harihar A.L. ^{[3
]}

机构：

[1] Department of Chemistry, SECAB Institute of Engineering and Technology, Vijayapur, 586101, Karnataka

[2] P.G. Department of Studies in Chemistry, S.B Arts KCP Science College, Vijaypur, 586103, Karnataka

[3] Department of Chemistry, Kittel Science College, Dharwad, 580003, Karnataka

来源：

Chemistry Africa | 2018年 / 1卷 / 1-2期

关键词：

Kinetics; Osmium(VIII); Pyrazinamide; Reaction mechanism;

D O I：

10.1007/s42250-018-0008-6

中图分类号：

学科分类号：

摘要：

The oxidation of an anti-tuberculosis drug, Pyrazinamide (PYZ) by Cu(III) complex has been investigated with and without Osmium(VIII) catalyst in aqueous alkaline media at constant ionic strength using spectrophotometer. The stoichiometric ratio was found to be 1:2 in both the cases. The reaction was unit order with respect to DPC and Os(VIII), whereas less than unity with respect to PYZ. The rate increased with increase in concentration of alkali and retarding effect was observed with increase in periodate concentration in both the cases. The oxidation product was identified and characterized by spectral analysis. A plausible mechanism was proposed and physical quantities such as activation parameters and thermodynamic quantities were determined with respect to slow step. Active species for Cu(III) and Os(VIII) were [Cu(H2IO6)(H20)2] and [OsO4(OH)2]−2 respectively. The reaction constants involved in different steps were calculated for both the cases. The catalytic constant (KC) for catalyzed reaction was calculated at different temperatures. © 2018, Springer Nature Switzerland AG.

引用

页码：53 / 66

页数：13

共 42 条

[1]

Yeager R., Munroe W., Pyrazinamide (Aldinamide) in the treatment of pulmonary tuberculosis, Am Rev Tuberc, 65, pp. 523-534, (1952)

[2]

Fox W., Ellard G.A., Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946–1986, with relevant subsequent publications, Int J Tuberc Lung Dis, 3, 10, pp. 231-279, (1999)

[3]

Wallace F.M., The chemotherapy of pulmonary tuberculosis: a Review, Chest, 76, pp. 785-796, (1979)

[4]

Society B.T., A controlled trial of 6 months’ chemotherapy in pulmonary tuberculosis Final report: results during the 36 months after the end of chemotherapy and beyond, Br J Dis Chest, 78, pp. 330-336, (1984)

[5]

Zhang Y., Mitchison D., Shi W., Zhang W., Mechanisms of pyrazinamide action and resistance, Microbiol Spectr, 2, pp. 1-12, (2014)

[6]

Vasquez-Campos L., Asencios-Solis L., Leo-Hurtado E., Quispe-Torres N., Salazar-Lindo E., Bayona J.B.M., Drug resistance trends among previously treated tuberculosis patients in a national registry in Peru, 1994–2001, Int J Tuberc Lung Dis, 8, pp. 465-472, (2004)

[7]

Zhang Y., Wade M., Scorpio A., Zhang H., Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid, J Antimicrob Chemother, 52, pp. 790-795, (2003)

[8]

Heifets L.B., Flory M.A., Lindholm-Levy P.J., Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?, Antimicrob Agents Chemother, 33, pp. 1252-1254, (1989)

[9]

Ellard G.A., Absorption, metabolism and excretion of pyrazinamide in man, Tubercle, 50, pp. 144-158, (1969)

[10]

Donald P.R., Maritz J.S., Diacon A.H., Pyrazinamide pharmacokinetics and efficacy in adults and children, Tuberculosis, 92, pp. 1-8, (2012)

← 1 2 3 4 5 →